Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nanjing To Invest RMB 10 Billion Over Next Three Years To Establish 'Drug Valley'

This article was originally published in PharmAsia News

Executive Summary

At the 2009 International Pharmaceutical Research and Cooperation Conference organized by Nanjing Municipal Government and Nanjing Commerce and the Trade Promotion Commission, it was revealed that the city will prioritize the financial support of establishing key biopharmaceutical companies' core technologies and platforms. To forge a world-class "drug valley," Nanjing will make efforts to jointly channel RMB 10 billion ($1.5 billion) on four levels - nation, province, city and district - from 2009 to 2012. This will lead corporations and various private capitals to invest more than RMB 100 billion. At the end of 2008, Nanjing housed more than 100 biopharmaceutical R&D and manufacturing companies, which formed the beginnings of an industry cluster. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072046

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel